A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer|Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer
Interventions: DRUG: Trastuzumab deruxtecan
Sponsor: AstraZeneca
Collaborators: Daiichi Sankyo Co., Ltd.